Mayne Pharma FY26 Results: Growth in Women's Health and DistributeRx
Key points
- Solid growth in Women's Health with BIJUVA® prescriptions up 26%
- Strong demand for NEXTSTELLIS® with a 15% increase in demand cycles
- DistributeRx launched, targeting over 2.5 million prescriptions per annum
- FY26 revenue of $383.7 million, gross margin of 64.7%
- Underlying EBITDA of $34.2 million, down 27% year-on-year
Full summary
Mayne Pharma Group Limited (ASX: MYX) announced its financial results for the year ended 30 June 2026 (FY26). The company reported revenue of $383.7 million, down 6% from the prior year, with gross margin expanding to 64.7%. The Women's Health portfolio saw significant growth, with BIJUVA® prescriptions up 26% and NEXTSTELLIS® demand cycles up 15%. The launch of DistributeRx, a direct-to-patient distribution platform, generated 62k total prescriptions in its first full quarter. Underlying EBITDA was $34.2 million, down 27% year-on-year, reflecting the impact of the Cosette transaction and increased marketing investments. The company expects to continue growing its Women's Health and DistributeRx portfolios in FY27.
Guidance
FY26 revenue: $383.7 million; Gross margin: 64.7%; Underlying EBITDA: $34.2 million
Outlook
Mayne Pharma plans to accelerate growth in Women's Health, expand the DistributeRx platform, and leverage the Salisbury investment for export growth in FY27.
Summary generated by a large language model. Please interpret with care.